June 6, 2013
/PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing non-toxic DCVax
personalized immune therapies for solid tumor cancers, today announced that its Chief Technical Officer, Dr.
, will make a presentation at the Brain Tumor Biotech Summit sponsored by the Weill Cornell Medical College and Voices Against Brain Cancer in
New York City
Friday, June 7
Dr. Bosch will review NW Bio's non-toxic personalized immune therapies for both operable and inoperable brain tumors, and the clinical trial programs for each of these.
This will include the ongoing 312-patient Phase III international trial of DCVax-L for Glioblastoma multiforme brain cancer, which is currently enrolling patients in both the US and Europe.
It will also include review of the Phase I/II trial of DCVax-Direct, which is expected to be launching soon for all inoperable solid tumors, including tumors that have metastasized to the brain from other locations.
Dr. Bosch will be presenting at the Weill Cornell Medical College's Uris Auditorium at
Friday, June 7, 2013
. The Auditorium is located at 1300 New York Avenue at 69
Street. Dr. Bosch's presentation will be available on the NW Bio Website starting at
10:00 am on Friday morning
June 7, 2013
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both
the United States
and Europe. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company's lead program is a 312-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer. The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I/II trials in multiple other cancers. The Company also conducted a Phase I/II trial with DCVax for metastatic ovarian cancer together with the University of Pennsylvania.